Sermorelin before and after: what actually changes, and when.

The honest sermorelin before and after is a blood test, not a photo. Two weeks of GHRH 1-29 put IGF-1 back in the young-adult range in older men. We found no trial that has ever measured adult body composition on sermorelin.

What can a sermorelin before and after honestly mean?

No sermorelin trial ever photographed anyone. The before-and-after that exists in the literature is a set of measured endpoints.

Those endpoints are growth hormone pulse profiles and serum IGF-1, plus CT-measured fat area and DEXA-measured lean mass across the wider GHRH-analog class.

Sermorelin is the unmodified first 29 amino acids of native GHRH. It acts one step upstream of GH at the pituitary, with a half-life of roughly 10–20 minutes, per Memdouh and colleagues in 2021.

Identity, regulatory history and mechanism are covered in our complete sermorelin guide. This article is only about the time-course.

Sermorelin sits in an unusual evidence position. It was FDA-approved as Geref from 1997 to 2008, so the pharmacology is settled.

But that approval was pediatric, and the adult-use claims were never taken through controlled trials. The result is a molecule with real measured afters on biomarkers, and essentially none on the outcomes the marketing photos imply.

What happens in weeks 1–2 on sermorelin?

Sermorelin's earliest change is pharmacological. A GHRH-receptor agonist triggers a GH pulse within the first hour. That acute response is why sermorelin served as a diagnostic stimulation agent under the Geref label.

The most direct before-and-after experiment ever run on this molecule came in 1992. Corpas and colleagues gave healthy older men GHRH 1-29 subcutaneously twice daily for 14 days, then measured the GH axis. The finding is stated in the paper’s own title.

Two weeks of dosing lifted 24-hour GH secretion and raised IGF-1 by roughly a third, back into the range typical of young adults, per Corpas and colleagues.

That's the strongest honest after in the entire sermorelin literature, and it's a blood test rather than a mirror. At day 14 the subjects looked identical to day 0.

The only noticeable changes in this window are the common early side effects: injection-site redness, transient flushing and mild water retention.

Why does the sermorelin IGF-1 rise plateau?

Sermorelin's IGF-1 rise plateaus by design. The peptide works through the intact hypothalamic–pituitary feedback loop, so rising IGF-1 and somatostatin push back on further GH release.

The elevation levels off near the young-adult range rather than escalating the way exogenous GH can. That physiologic ceiling is both the strongest argument for the GHRH-analog approach and the reason the after is inherently modest.

The longest well-controlled time-course comes from Khorram and colleagues, who gave older men and women a nightly GHRH 1-29 analog for 16 weeks.

The IGF-1 elevation appeared early and held through the full study, so the pituitary didn't desensitize. The accompanying endocrine and metabolic effects were modest rather than transformative, per Khorram and colleagues in 1997.

Tesamorelin

Stabilized GHRH 44 aa FDA-approved analog

Sermorelin itself is not currently stocked at Peptriva. Tesamorelin is the closest stocked GHRH analog — the stabilized descendant whose measured 6-month readouts anchor the class comparisons in this review. Lab-verified identity and purity.

Shop Tesamorelin

What does sermorelin do to body composition?

Nobody has measured it. Weeks 4 to 12 is the window every before-and-after photo implies, and it's exactly where the sermorelin-specific evidence stops.

There are 0 randomized controlled trials of sermorelin for adult body composition, performance or senescence endpoints since 2020. A 2026 Sports Medicine review by Mendias and Awan classifies its claimed benefits as mechanism-based rather than trial-validated.

The adult literature that does exist is conceptual. Sinha and colleagues in 2020 is the example: a review grouping GH secretagogues as candidate tools for body-composition management, not interventional data.

To calibrate what you should expect, look at the one GHRH analog with modern instrumented trials. In a 2024 randomized, double-blind substudy from Russo and colleagues, six months of tesamorelin cut CT-measured visceral fat by a median of 25 cm².

The comparison group gained 14 cm² over the same period, and liver fat fell 4.2 percentage points. That's what a real GHRH-analog after looks like at 6 months: meaningful on a CT scan, invisible across a room.

Sermorelin is a shorter-acting agonist at the same receptor. If it moves body composition at all, we'd expect that scale or smaller. Our tesamorelin vs sermorelin comparison works through why.

Do sermorelin’s sleep and recovery claims hold up?

Three longer-horizon sermorelin claims dominate the marketing, and none of them has an outcome trial. Each deserves its own honesty check.

Sleep. The mechanism is real. GHRH itself promoted slow-wave sleep in controlled polysomnography studies of healthy men, per Kerkhofs and colleagues in 1993, and altered sleep is among the most commonly reported subjective effects.

But that study used native GHRH in young adults. No modern sermorelin trial has quantified sleep-architecture outcomes in the populations the marketing targets.

Recovery and healing. Mechanism-only. GH and IGF-1 participate in tissue repair, but no controlled sermorelin trial has measured recovery, injury or musculoskeletal endpoints. Mendias and Awan say so plainly.

Axis restoration. The idea that sustained sermorelin use re-trains a flagging somatotropic axis traces largely to a 2006 opinion piece by Walker, proposing sermorelin as a more physiologic alternative to recombinant GH.

It's a coherent hypothesis, with pulsatility preserved and feedback intact, that has never been tested as a long-term outcome trial. We'd treat it as a rationale rather than a result, and so should you.

The class also cautions against assuming biomarker change cascades into felt outcomes. In a 2025 randomized trial of 73 patients, tesamorelin moved the measurable endpoints: waist circumference fell 2.7 cm versus standard of care.

The cognitive outcomes it was testing didn't improve, per Ellis and colleagues in 2025. A biomarker moving is the beginning of the question, not the answer.

Which sermorelin before-and-after claims does no trial support?

Five sermorelin claims appear routinely in promotions and are supported by no controlled trial, anywhere, at any date.

• Dramatic transformation photos. No sermorelin RCT has measured fat mass in adults; the only instrumented GHRH-analog fat data belongs to tesamorelin, and it is CT-modest.
• Visible lean-mass claims. No trial has shown appreciable lean-mass gain in healthy adults on any sermorelin protocol.
• “Look 10 years younger” skin reversal. No sermorelin study has measured skin endpoints.
• Guaranteed sleep transformation. Mechanistically plausible, never quantified for sermorelin in a modern trial.
• “Clinically proven” longevity-clinic claims. The clinical proof is a pediatric GHD approval that ended in 2008 plus two small 1990s biomarker studies — not an adult outcomes base.

Transformation photos carry a second, structural problem: you can't verify them, and they're confounded. Training, diet, other compounds and lighting all travel with the image, and so does simple selection, because only responders get photographed.

Here are the questions we'd ask of any sermorelin before-and-after claim.

• Is the change instrument-measured (IGF-1 assay, CT, DEXA, polysomnography) or photographic?
• Was there a control group, in a comparable population?
• Is the effect from sermorelin itself, or borrowed from tesamorelin or GH data?
• Does the claimed timeline match the pharmacology — biomarkers in weeks, composition in months, if at all?
• Who benefits from the claim, and would it survive the trial that has never been run?

Tesamorelin

5 mg ≥99% pure Lyophilized

44-aa stabilized GHRH analog with a trans-3-hexenoyl modification — the reference compound behind the measured 6-month readouts cited in this review. COA from an ISO 17025 lab with each lot.

Learn more